Immunotherapy of Neuroendocrine Neoplasms: Any Role for the Chimeric Antigen Receptor T Cells?
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunotherapy of Neuroendocrine Neoplasms: Any Role for the Chimeric Antigen Receptor T Cells?
Authors
Keywords
-
Journal
Cancers
Volume 14, Issue 16, Pages 3991
Publisher
MDPI AG
Online
2022-08-19
DOI
10.3390/cancers14163991
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer
- (2022) Loïc Reppel et al. Journal for ImmunoTherapy of Cancer
- Immune Checkpoint Blockade in Lung Carcinoids with Aggressive Behaviour: One More Arrow in Our Quiver?
- (2022) Sergio Di Molfetta et al. Journal of Clinical Medicine
- Addition of Immune Checkpoint Inhibitors to Chemotherapy vs Chemotherapy Alone as First-Line Treatment in Extensive-Stage Small-Cell Lung Carcinoma: A Systematic Review and Meta-Analysis
- (2022) Edurne Arriola et al. Oncology and Therapy
- Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
- (2022) Robert I Haddad et al. Journal of the National Comprehensive Cancer Network
- CAR T cells in solid tumors: challenges and opportunities
- (2021) Faroogh Marofi et al. Stem Cell Research & Therapy
- Small-cell lung cancer
- (2021) Charles M. Rudin et al. Nature Reviews Disease Primers
- Immunotherapy in Neuroendocrine Neoplasms: Where Are We Now?
- (2021) Nicola Fazio et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
- (2021) A.-M.C. Dingemans et al. ANNALS OF ONCOLOGY
- "Present and future of immunotherapy in Neuroendocrine Tumors"
- (2021) Manuela Albertelli et al. REVIEWS IN ENDOCRINE & METABOLIC DISORDERS
- CAR-T cell therapy: current limitations and potential strategies
- (2021) Robert C. Sterner et al. Blood Cancer Journal
- Novel, non-invasive markers for detecting therapy induced neuroendocrine differentiation in castration-resistant prostate cancer patients
- (2021) Divya Bhagirath et al. Scientific Reports
- Survival and pretreatment prognostic factors for extensive‐stage small cell lung cancer: A comprehensive analysis of 358 patients
- (2021) Li‐Ling Huang et al. Thoracic Cancer
- Immune Checkpoint Inhibitors: New Weapons Against Medullary Thyroid Cancer?
- (2021) Sergio Di Molfetta et al. Frontiers in Endocrinology
- Therapy considerations in neuroendocrine prostate cancer: what next?
- (2021) Himisha Beltran et al. ENDOCRINE-RELATED CANCER
- Molecular events in neuroendocrine prostate cancer development
- (2021) Yong Wang et al. Nature Reviews Urology
- Update on Targeted Therapy in Medullary Thyroid Cancer
- (2021) Christian Okafor et al. Frontiers in Endocrinology
- A highly-specific fully-human antibody and CAR-T cells targeting CD66e/CEACAM5 are cytotoxic for CD66e-expressing cancer cells in vitro and in vivo
- (2021) Du-San Baek et al. CANCER LETTERS
- Enhanced AC133-specific CAR T cell therapy induces durable remissions in mice with metastatic small cell lung cancer
- (2021) Sanaz Taromi et al. CANCER LETTERS
- Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
- (2021) Apar Kishor P. Ganti et al. Journal of the National Comprehensive Cancer Network
- CAR-T Cell Therapy in Cancer: Tribulations and Road Ahead
- (2020) Qingyang Zhang et al. Journal of Immunology Research
- Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study
- (2020) Charles M. Rudin et al. JOURNAL OF CLINICAL ONCOLOGY
- HITM-SURE: Hepatic immunotherapy for metastases phase Ib anti-CEA CAR-T study utilizing pressure enabled drug delivery
- (2020) Steven C Katz et al. Journal for ImmunoTherapy of Cancer
- Emerging Therapies in Pheochromocytoma and Paraganglioma: Immune Checkpoint Inhibitors in the Starting Blocks
- (2020) Giuseppe Fanciulli et al. Journal of Clinical Medicine
- Eradication of neuroblastoma by T cells redirected with an optimized GD2-specific chimeric antigen receptor and interleukin-15
- (2019) Yuhui Chen et al. CLINICAL CANCER RESEARCH
- Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions
- (2019) Marco Gallo et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Notch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challenges
- (2019) Alessandro Leonetti et al. CELLULAR ONCOLOGY
- HITM-SIR: phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA+ liver metastases
- (2019) Steven C. Katz et al. CANCER GENE THERAPY
- Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma
- (2019) John K. Lin et al. JOURNAL OF CLINICAL ONCOLOGY
- DLL3: an emerging target in small cell lung cancer
- (2019) Dwight H. Owen et al. Journal of Hematology & Oncology
- Non-conventional doses of somatostatin analogs in patients with progressing well differentiated neuroendocrine tumor
- (2019) Giuseppe Lamberti et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Neuroendocrine Cancer of the Prostate
- (2019) Noémi Kránitz et al. PATHOLOGY & ONCOLOGY RESEARCH
- Clinical features of neuroendocrine prostate cancer
- (2019) Vincenza Conteduca et al. EUROPEAN JOURNAL OF CANCER
- Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
- (2019) Luis Paz-Ares et al. LANCET
- Emerging multitarget tyrosine kinase inhibitors in the treatment of neuroendocrine neoplasms
- (2018) Federica Grillo et al. ENDOCRINE-RELATED CANCER
- Antitumor activity of CD56-chimeric antigen receptor T cells in neuroblastoma and SCLC models
- (2018) Denise L. Crossland et al. ONCOGENE
- Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer
- (2018) John K. Lee et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
- (2018) Leora Horn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Management of Medullary Thyroid Cancer
- (2018) David Viola et al. ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA
- The safety of available treatments options for neuroendocrine tumors
- (2017) A. Faggiano et al. Expert Opinion On Drug Safety
- Trends in the presentation, treatment, and survival of patients with medullary thyroid cancer over the past 30 years
- (2017) Reese W. Randle et al. SURGERY
- Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
- (2017) Arvind Dasari et al. JAMA Oncology
- Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives
- (2017) J. Gauthier et al. Current Research in Translational Medicine
- Medullary Carcinoma
- (2017) R. Michael Tuttle et al. Journal of the National Comprehensive Cancer Network
- Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors
- (2016) Manisha H. Shah et al. INVESTIGATIONAL NEW DRUGS
- Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and 68Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial
- (2016) C. Bodet-Milin et al. JOURNAL OF NUCLEAR MEDICINE
- Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer
- (2016) Himisha Beltran et al. NATURE MEDICINE
- ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site
- (2016) M. Pavel et al. NEUROENDOCRINOLOGY
- Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases
- (2015) S. C. Katz et al. CLINICAL CANCER RESEARCH
- Expression of cadherin 17 in well-differentiated neuroendocrine tumours
- (2015) Anthony N Snow et al. HISTOPATHOLOGY
- Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma
- (2015) Samuel A. Wells et al. THYROID
- Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation
- (2014) Jonathan I. Epstein et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- CD133+ Cancer Stem-like Cells in Small Cell Lung Cancer Are Highly Tumorigenic and Chemoresistant but Sensitive to a Novel Neuropeptide Antagonist
- (2014) S. Sarvi et al. CANCER RESEARCH
- Neuroendocrine tumors: insights into innovative therapeutic options and rational development of targeted therapies
- (2013) Federica Barbieri et al. DRUG DISCOVERY TODAY
- Current Understanding and Management of Medullary Thyroid Cancer
- (2013) M. Roy et al. ONCOLOGIST
- The Basic Principles of Chimeric Antigen Receptor Design
- (2013) Michel Sadelain et al. Cancer Discovery
- Cadherin-17 is a useful diagnostic marker for adenocarcinomas of the digestive system
- (2008) Min-Cheng Su et al. MODERN PATHOLOGY
- Current Management of Medullary Thyroid Cancer
- (2008) R. S. Sippel et al. ONCOLOGIST
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now